首页> 外文期刊>European archives of oto-rhino-laryngology: Official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) >Intensity-modulated radiotherapy in definitive oncological treatment of hypopharyngeal squamous cell carcinoma
【24h】

Intensity-modulated radiotherapy in definitive oncological treatment of hypopharyngeal squamous cell carcinoma

机译:强度调节的过度肿瘤细胞癌的最终肿瘤治疗的放射治疗

获取原文
获取原文并翻译 | 示例
           

摘要

Hypopharyngeal squamous cell carcinoma (HSCC) is treated by definitive concomitant chemoradiotherapy at most centres. Intensity-modulated radiotherapy (IMRT) is an advanced computer-controlled high-precision radiotherapy technique that has been used at our institution in the treatment of HSCC since 2002. Our aim was to review the treatment results of IMRT-based chemoradiotherapy (CRT) in patients diagnosed with HSCC. The cohort comprised all patients with previously untreated, biopsy-proven squamous cell carcinoma of the hypopharynx treated by definitive CRT using IMRT between March 2002 and November 2010. All patients were diagnosed M0. Forty-five eligible patients were identified. Six patients were treated by radiotherapy alone and 39 patients received concomitant chemotherapy. All patients had a minimum follow-up of 3 years or until death. Complete response was achieved in 29/45 (64 %) patients. Salvage surgery was performed on 10/16 patients with incomplete response. The 5-year estimates for overall survival, disease-specific survival, and local control in the whole cohort were 31, 45, and 64 %, respectively. Classifications T4 and N2c-N3 were prognostic for worse survival. None of the surviving patients needed permanent tracheotomy or PEG tube. We conclude that survival after IMRT-based CRT remained unsatisfactory with frequent relapses at distant sites. The outcome figures were comparable with those that have been achieved by surgery and postoperative radiotherapy. However, all the surviving patients in the current study cohort could retain their functioning larynx. These results using IMRT-based definitive CRT as the primary option for the treatment of HSCC support its continued usage for the delivery of radiotherapy.
机译:低聚鳞状细胞癌(HSCC)在大多数中心的明确伴随的化学疗法治疗。强度调制的放射疗法(IMRT)是一种先进的计算机控制的高精度放射治疗技术,自2002年以来,我们的机构已用于治疗HSCC。我们的目的是审查基于IMRT的化学疗法(CRT)的治疗结果患有HSCC的患者。队列组成所有患有先前未经治疗的活检的患者,在2002年3月至2010年3月之间使用IMRT治疗的后期治疗的患者的鳞癌鳞状细胞癌。所有患者均被诊断为M0。确定了四十五名符合条件的患者。单独放疗六名患者,39名患者接受伴随化疗。所有患者均未发生3年或直至死亡。在29/45(64%)患者中取得了完整响应。在10/16患者中进行抢救手术,不完全反应。整个群组的整体存活,疾病特异性生存和局部对照的5年估计分别为31,45和64%。分类T4和N2C-N3是预后的损失。没有幸存的患者需要永久气管切开术或PEG管。我们得出结论,在基于IMRT的CRT之后存活仍然不满意,在遥远的位置频繁复发。结果数字与通过手术和术后放射治疗实现的结果相当。然而,目前研究队列中的所有存活的患者都可以保留其功能喉。这些结果采用基于IMRT的最终CRT作为HSCC处理的主要选择支持其继续使用放疗的递送。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号